| Foundations Behavioral Health, Llc | |
|
1218 N Florence Ave Ste B Claremore OK 74017-3755 | |
| (918) 508-9696 | |
| Not Available |
| Full Name | Foundations Behavioral Health, Llc |
|---|---|
| Speciality | Counselor |
| Location | 1218 N Florence Ave Ste B, Claremore, Oklahoma |
| Authorized Official Name and Position | Grace Ballard (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 9185089696 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Foundations Behavioral Health, Llc 1218 N Florence Ave Ste B Claremore OK 74017-3755 Ph: (918) 508-9696 | Foundations Behavioral Health, Llc 1218 N Florence Ave Ste B Claremore OK 74017-3755 Ph: (918) 508-9696 |
| NPI Number | 1326429598 |
|---|---|
| Provider Enumeration Date | 06/14/2015 |
| Last Update Date | 01/20/2016 |
| Medicare PECOS PAC ID | 4981950862 |
|---|---|
| Medicare Enrollment ID | O20180706001976 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326429598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Provider Name | Grace Ballard |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1902137631 PECOS PAC ID: 1759516156 Enrollment ID: I20131019000047 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Vanessa L Brown |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710229612 PECOS PAC ID: 1456601475 Enrollment ID: I20180912000658 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Cheri L Doyle |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1508326877 PECOS PAC ID: 9638411044 Enrollment ID: I20190506001918 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Shakendra M Leathers |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1699073379 PECOS PAC ID: 3678974631 Enrollment ID: I20210628002762 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Cheri J Moberly |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1568763993 PECOS PAC ID: 9335491554 Enrollment ID: I20230630000573 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Christian K Morgan |
|---|---|
| Provider Type | Practitioner - Marriage And Family Therapist |
| Provider Identifiers | NPI Number: 1023245529 PECOS PAC ID: 5395195523 Enrollment ID: I20231229000983 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
| Provider Name | Christine E Johnson |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1861147787 PECOS PAC ID: 6800247222 Enrollment ID: I20240208000866 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.
UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.
In what researchers state is the first pilot clinical trial to assess the effects of resveratrol on pain severity and levels of inflammatory biomarkers in patients with mild to moderate knee osteoarthritis, the scientists compared treatment with a nonsteroidal anti-inflammatory drug combined with either resveratrol or placebo over 90 days.
Biomedical engineers at Johns Hopkins have developed a new liquid material that in early experiments in rats and humans shows promise in restoring damaged soft tissue relatively safely and durably.
› Verified 9 days ago
Youthcare Of Oklahoma Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 603 W 12th St, Claremore, OK 74017 Phone: 866-926-6552 Fax: 918-289-0551 | |
Jeffrey K Mcilroy Md Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2990 N Sioux Ave, Claremore, OK 74017 Phone: 918-342-2622 Fax: 918-342-2641 | |
Yco Alliance Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1402 N Florence Ave Ste B, Claremore, OK 74017 Phone: 918-608-0380 Fax: 918-770-9337 | |
Rogers County Youth Services, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2680 N Highway 88, Claremore, OK 74017 Phone: 918-341-7580 Fax: 918-341-7977 | |
Grand Mental Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 17599 S Highway 88, Claremore, OK 74017 Phone: 918-342-0770 | |
A Peace Within, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1222 N Florence Ave, Suite A, Claremore, OK 74017 Phone: 918-697-4201 | |
Rogers County Training Center, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2112 El Anderson Blvd, Claremore, OK 74017 Phone: 918-341-5936 |